Early OCT angiography changes of type 1 CNV in exudative AMD treated with anti-VEGF

Macular Diseases

Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry

Ophthalmology.

Rao P, Lum F, Wood K, Salman C, Burugapalli B, Hall R, Singh S, Parke DW 2nd2, Williams GA

doi: 10.1016/j.ophtha.2017.10.010.

Blindness and Vision ImpairmentMacular Diseases

Early predictive factors of visual loss at 1-year in neovascular age-related macular degeneration under anti-VEGF in the GEFAL study

Ophthalmol Retina

Kodjikian L, Rezkallah A, Decullier E, Aulagner G, Huot L, Mathis T, GEFAL Study Group.

doi: 10.1016/j.oret.2021.04.015

COMMENTED

Macular Diseases

Two-Year Risk of Exudation in Eyes with Non-Exudative AMD and Subclinical Neovascularization Detected with Swept Source OCT Angiography

Am J Ophthalmol.

Yang J, Zhang Q, Motulsky EH, Thulliez M, Shi Y, Lyu C, de Sisternes L, Durbin MK, Feuer W, Wang RK, Gregori G, Rosenfeld PJ

doi: 10.1016/j.ajo.2019.06.017.

COMMENTED

Early retinal and choroidal OCT and OCT angiography signs of inflammation after uncomplicated cataract surgery

Br J Ophthalmol.

Pilotto E, Leonardi F, Stefanon G, Longhin E, Torresin T, Deganello D, Cavarzeran F, Miglionico G, Parrozzani R, Midena E

doi: 10.1136/bjophthalmol-2018-312461.

Macular DiseasesRetinal Diseases

OCT-based biomarkers for predicting treatment response in eyes with centre-involved diabetic macular oedema treated with anti-VEGF injections: a real-life retina clinic-based study

Br J Ophthalmol

Szeto SK, Hui VWK, Tang FY, Yang D, Sun ZH, Mohamed S, Chan CKM, Lai TYY, Cheung C

doi: 10.1136/bjophthalmol-2021-319587

Macular DiseasesFurther Publications

Real-world outcomes of anti-VEGF therapy in treatment-naïve neovascular age-related macular degeneration diagnosed on OCT angiography: the REVEAL study

Acta Ophthalmol

Lupidi M, Schiavon S, Cerquaglia A, Fruttini D, Gujar R, Muzi A, Fiore T, Reibaldi M, Chhablani J, Cagini C

doi: 10.1111/aos.15005

COMMENTED

Macular Diseases

Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD

Sci Rep.

Reid CA, Nettesheim ER, Connor TB, Lipinski DM

doi: 10.1038/

Macular Diseases

Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial

JAMA Ophthalmol.

Bressler SB, Odia I, Maguire MG, Dhoot DS, Glassman AR, Jampol LM, Marcus DM, Solomon SD, Sun JK; Diabetic Retinopathy Clinical Research Network

doi: 10.1001/jamaophthalmol.

Macular Diseases

Changes in neovascular activity following fixed dosing with an anti-vascular endothelial growth factor agent over 52 weeks in the phase III VIEW 1 and VIEW 2 studies

Br J Ophthalmol.

Moshfeghi DM, Thompson D, Saroj N

doi: 10.1136/bjophthalmol-2019-315021.

Related content

Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry

Early predictive factors of visual loss at 1-year in neovascular age-related macular degeneration under anti-VEGF in the GEFAL study

Two-Year Risk of Exudation in Eyes with Non-Exudative AMD and Subclinical Neovascularization Detected with Swept Source OCT Angiography

Early retinal and choroidal OCT and OCT angiography signs of inflammation after uncomplicated cataract surgery

OCT-based biomarkers for predicting treatment response in eyes with centre-involved diabetic macular oedema treated with anti-VEGF injections: a real-life retina clinic-based study

Real-world outcomes of anti-VEGF therapy in treatment-naïve neovascular age-related macular degeneration diagnosed on OCT angiography: the REVEAL study

Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD

Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial

Changes in neovascular activity following fixed dosing with an anti-vascular endothelial growth factor agent over 52 weeks in the phase III VIEW 1 and VIEW 2 studies